# An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

> **NCT02245737** · PHASE2,PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 2218 (actual)

## Conditions studied

- Alzheimer´s Disease

## Interventions

- **DRUG:** Lanabecestat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02245737
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09-30
- **Primary completion:** 2018-10-04
- **Final completion:** 2018-10-04
- **Target enrollment:** 2218 (ACTUAL)
- **Why stopped:** An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility
- **Last updated:** 2019-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02245737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02245737, "An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02245737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*